Copley Acquisition Corp (COPL) · Oct 9, 2026 · New debt
$900K sponsor note — Maximum principal raised from $450,000 to $900,000
Copley Acquisition amended its convertible note, doubling sponsor funding capacity to $900,000 while adding potential below-IPO dilution.
Copley is a SPAC trying to complete its announced combination with Ignite Proteomics, a precision-oncology protein-analytics company; the transaction remains the central business objective rather than operating-company growth. The filing adds funding capacity, not completed funding. Copley replaced its existing sponsor note and doubled the maximum available working-capital facility to $900,000. 〔0〕
| Item | Filing terms |
|---|---|
| Maximum sponsor note | $900,000, up from $450,000 (Note) |
| Interest rate | 0% (Note terms) |
| Conversion price | $7.00 per unit (Working Capital Units) |
| Potential units at full conversion | Approximately 128,571, inferred from $900,000 ÷ $7.00 |
| Securities per unit | One ordinary share plus one-half warrant (Working Capital Units) |
| Warrant exercise price | $11.50 per share (Working Capital Units) |
The immediate benefit is runway into the merger process. The sponsor can advance cash in monthly tranches for working capital, and the note is repayable at the business combination or liquidation date. That matters because Copley recently moved toward extending its SPAC timeline while pursuing the Ignite transaction, so the facility supports the administrative and transaction costs of keeping the deal alive.
The support comes with meaningful potential dilution, but it is not dilution today. The sponsor may convert outstanding amounts at $7 per unit, below Copley’s $10 IPO unit price, into shares and warrants. Full use and conversion would imply roughly 128,571 units, including approximately 128,571 shares and 64,286 warrants; however, the filing does not say that the full $900,000 has been drawn or converted. The note also bears no interest, limiting cash-cost pressure compared with ordinary debt. 〔1〕
Bottom line: This is a modestly supportive financing amendment for completing the Ignite transaction, offset by a cheaper sponsor conversion feature that could dilute holders if the facility is used and converted. It extends deal runway, but does not itself improve the merger’s closing certainty.
Shareholder vote on SPAC deadline extension
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!